Parallax Volatility Advisers
CUE icon

Parallax Volatility Advisers’s Cue Biopharma CUE Stock Holding History

Parallax Volatility Advisers’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-460
Closed -$67K – 2954
2022
Q1 		$67K Hold
460
– – ﹤0.01% 2430
2021
Q4 		$156K Buy
+460
New +$178K ﹤0.01% 2524

Other funds holding CUE

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Parallax Volatility Advisers's CUE Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Cue Biopharma (CUE) in Q2 2023, closing a stake of 2,500 shares — an estimated $268K sold.

Parallax Volatility Advisers first reported a position in CUE in Q2 2021 and held it in 7 quarters. The position peaked at $1.13M in Q4 2021. 78 funds tracked by Wall St. Rank hold CUE as of Q2 2023.

  • Parallax Volatility Advisers reported no remaining Cue Biopharma position as of Q2 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,500 Cue Biopharma shares in Q2 2023, an estimated $268K.
  • Parallax Volatility Advisers first reported a position in Cue Biopharma in Q2 2021 and held it in 7 quarters.
  • Parallax Volatility Advisers's Cue Biopharma position peaked at $1.13M in Q4 2021.
  • 78 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.